JP2003522724A - 医薬製剤のための酸化防止剤−安定剤系 - Google Patents

医薬製剤のための酸化防止剤−安定剤系

Info

Publication number
JP2003522724A
JP2003522724A JP2000543139A JP2000543139A JP2003522724A JP 2003522724 A JP2003522724 A JP 2003522724A JP 2000543139 A JP2000543139 A JP 2000543139A JP 2000543139 A JP2000543139 A JP 2000543139A JP 2003522724 A JP2003522724 A JP 2003522724A
Authority
JP
Japan
Prior art keywords
acid
group
carboxylic acid
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000543139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003522724A5 (https=
Inventor
ラング，フィリップ・シー
Original Assignee
ロバーツ・ラボラトリーズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロバーツ・ラボラトリーズ・インコーポレーテッド filed Critical ロバーツ・ラボラトリーズ・インコーポレーテッド
Publication of JP2003522724A publication Critical patent/JP2003522724A/ja
Publication of JP2003522724A5 publication Critical patent/JP2003522724A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
JP2000543139A 1998-04-08 1998-11-16 医薬製剤のための酸化防止剤−安定剤系 Pending JP2003522724A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/057,260 1998-04-08
US09/057,260 US5962488A (en) 1998-04-08 1998-04-08 Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
PCT/US1998/024471 WO1999052529A1 (en) 1998-04-08 1998-11-16 Antioxidant stabilizer system for pharmaceutical formulations

Publications (2)

Publication Number Publication Date
JP2003522724A true JP2003522724A (ja) 2003-07-29
JP2003522724A5 JP2003522724A5 (https=) 2006-01-05

Family

ID=22009506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000543139A Pending JP2003522724A (ja) 1998-04-08 1998-11-16 医薬製剤のための酸化防止剤−安定剤系

Country Status (7)

Country Link
US (2) US5962488A (https=)
EP (1) EP1067927B1 (https=)
JP (1) JP2003522724A (https=)
AT (1) ATE318598T1 (https=)
CA (1) CA2327708A1 (https=)
DE (1) DE69833684T2 (https=)
WO (1) WO1999052529A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521995A (ja) * 2015-06-23 2018-08-09 インターベット インターナショナル ベー． フェー． 衛生化飲料水と共に使用するためのビタミンｅを含有するイソオキサゾリン溶液

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
WO2000042997A1 (en) * 1999-01-21 2000-07-27 Shionogi & Co., Ltd. Medicinal compositions retarded in the discoloration of phenolic hydroxyl compounds
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2007046411A1 (ja) * 2005-10-19 2007-04-26 Dainippon Sumitomo Pharma Co., Ltd. イソキサゾール化合物の安定化方法
DE102007025275A1 (de) * 2007-05-31 2008-12-04 Qiagen Gmbh Butendisäure oder deren Derivate zur Behandlung einer biologischen Probe
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
EP2309985B1 (en) * 2008-07-28 2018-03-14 Takeda Pharmaceutical Company Limited Pharmaceutical composition
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
TWI473628B (zh) * 2009-07-22 2015-02-21 用於對氧化敏感之類鴉片藥劑之抗破壞劑型
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
AU2012289764B2 (en) 2011-07-29 2017-03-02 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
ES2648129T3 (es) 2011-07-29 2017-12-28 Grünenthal GmbH Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP4221704B1 (en) * 2020-10-01 2025-09-24 Imago Biosciences Inc. Pharmaceutical formulations for treating diseases mediated by kdm1a

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB682205A (en) * 1949-03-16 1952-11-05 Eastman Kodak Co Improvements in and relating to anti-oxidants for oils and fats
JPS5434063B2 (https=) * 1976-02-12 1979-10-24
JPS62153385A (ja) * 1985-12-27 1987-07-08 Riken Vitamin Co Ltd 酸化防止剤
JPH05339154A (ja) * 1992-06-03 1993-12-21 Sagami Chem Res Center 肝機能改善剤
JPH06500594A (ja) * 1991-01-07 1994-01-20 カビ　ファルマシア　アクチェボラーグ 多不飽和油の安定化のための天然酸化防止剤の組成物
JPH0717855A (ja) * 1992-09-02 1995-01-20 Maruha Corp 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
JPH09194362A (ja) * 1996-01-19 1997-07-29 Bizen Kasei Kk ドコサヘキサエン酸及びエイコサペンタエン酸含有リン脂質を含む組成物
JPH09235584A (ja) * 1996-03-01 1997-09-09 Nof Corp 油脂組成物及びそれを含む食品

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB679192A (en) * 1948-07-09 1952-09-17 Eastman Kodak Co Method of stabilizing fats and fatty oils against oxidation
US4091091A (en) * 1973-11-08 1978-05-23 Eli Lilly And Company Stabilized nitroglycerin tablets
US4837031A (en) * 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
DK0471515T3 (da) * 1990-08-15 1997-07-21 Lilly Co Eli Ringsubstituerede 2-amino-1,2,3,4-tetrahydronphtalener, 3-aminochromaner og 3-aminothiochromaner
US5077069A (en) * 1991-01-07 1991-12-31 Kabi Pharmacia Ab Composition of natural antioxidants for the stabilization of polyunsaturated oils
US5434174A (en) * 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
CA2173467A1 (en) * 1993-10-25 1995-05-04 Keith D. Ertel A stable pharmaceutical composition of terfenadine and ibuprofen
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB682205A (en) * 1949-03-16 1952-11-05 Eastman Kodak Co Improvements in and relating to anti-oxidants for oils and fats
JPS5434063B2 (https=) * 1976-02-12 1979-10-24
JPS62153385A (ja) * 1985-12-27 1987-07-08 Riken Vitamin Co Ltd 酸化防止剤
JPH06500594A (ja) * 1991-01-07 1994-01-20 カビ　ファルマシア　アクチェボラーグ 多不飽和油の安定化のための天然酸化防止剤の組成物
JPH05339154A (ja) * 1992-06-03 1993-12-21 Sagami Chem Res Center 肝機能改善剤
JPH0717855A (ja) * 1992-09-02 1995-01-20 Maruha Corp 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
JPH09194362A (ja) * 1996-01-19 1997-07-29 Bizen Kasei Kk ドコサヘキサエン酸及びエイコサペンタエン酸含有リン脂質を含む組成物
JPH09235584A (ja) * 1996-03-01 1997-09-09 Nof Corp 油脂組成物及びそれを含む食品

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521995A (ja) * 2015-06-23 2018-08-09 インターベット インターナショナル ベー． フェー． 衛生化飲料水と共に使用するためのビタミンｅを含有するイソオキサゾリン溶液

Also Published As

Publication number Publication date
ATE318598T1 (de) 2006-03-15
EP1067927A1 (en) 2001-01-17
US5962488A (en) 1999-10-05
EP1067927B1 (en) 2006-03-01
EP1067927A4 (en) 2003-04-23
WO1999052529A1 (en) 1999-10-21
DE69833684D1 (de) 2006-04-27
US6479529B1 (en) 2002-11-12
CA2327708A1 (en) 1999-10-21
DE69833684T2 (de) 2006-11-16

Similar Documents

Publication Publication Date Title
JP2003522724A (ja) 医薬製剤のための酸化防止剤−安定剤系
US4937267A (en) Method of treatment of obesity
KR100236562B1 (ko) 트라마돌 및 비-스테로이드성 소염제를 함유하는 조성물
JP2019131578A (ja) 医薬配合剤
KR102372194B1 (ko) Lsd1 억제제를 이용한 다발성 경화증의 치료방법
HUP0104693A2 (hu) Eljárás az ízületi gyulladás MEK inhibitorokkal való kezelésére
JP4048024B2 (ja) 新規経口製剤
BRPI0609952A2 (pt) métodos para modular a função da bexiga
PT85799B (pt) Processo para a preparacao de fenilalquilaminas e de composicoes farmaceuticas contendo-as
JPH07196498A (ja) Ｌｄｌの酸化およびアテローム性動脈硬化症を防ぐための医薬組成物
JP2007506435A (ja) 神経ペプチドｆｆ受容体２アゴニストによる神経因性疼痛の処置
JP2003012557A (ja) 不安及びうつ病のための多剤併用治療
JP2002501890A (ja) 光学的に純粋な（＋）−ビュープロピオンの薬学的使用
JP2003526663A (ja) Ｃｏｍｔ阻害剤の鎮痛剤としての用途
US6562858B2 (en) Method for treating depression
JP2005531612A (ja) ネフォパムの製剤および痛みの治療におけるその使用
CN100339073C (zh) 作为血清素拮抗剂用于治疗肥胖的芳基磺酰胺
JP5993303B2 (ja) リウマチ性痛を治療するための１−フェニル−３−ジメチルアミノプロパン化合物の使用
JP2022523499A (ja) チアゾリン抗痛覚過敏薬を用いて疼痛を処置する方法
HU214588B (hu) Eljárás bicikloheptán-származékot tartalmazó, CCK-rendszer gátló hatású gyógyászati készítmények előállítására
HU228775B1 (hu) 6-(Dimetilamino-metil)-1-fenil-ciklohexán vegyületek felhasználása vizeletinkontinencia kezelésére és ezeket tartalmazó gyógyszerkészítmények
CA3176643A1 (en) Use of dopamine d3 partial agonists for treating central nervous system disorders
EP3307267B1 (en) Multiple sclerosis treatment
CN115697316B (zh) 加巴喷丁和酮洛芬的协同掺加物、药物组合物及其医疗用途
CN114761017B (zh) 用于疼痛疾患的米氮平和替扎尼定组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090717